Influenza virus vaccine - AVANT Immunotherapeutics/Aventis Pasteur

Drug Profile

Influenza virus vaccine - AVANT Immunotherapeutics/Aventis Pasteur

Latest Information Update: 05 Jun 2002

Price : $50

At a glance

  • Originator sanofi pasteur
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Influenza virus infections

Most Recent Events

  • 05 Jun 2002 Discontinued - Phase-II for Influenza virus infections in Peru (IM)
  • 05 Jun 2002 Discontinued - Phase-I for Influenza virus infections in France (IM)
  • 24 Dec 1999 Pasteur Mérieux Connaught is now a subsidiary of Aventis and its new name is Aventis Pasteur
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top